APUS
Apimeds Pharmaceuticals US, Inc.APUS
APUS
About: Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Employees: 2
0
Funds holding %
of 7,428 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0.25% more ownership
Funds ownership: 0% [Q1] → 0.25% (+0.25%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for APUS.
Financial journalist opinion
Neutral
Business Wire
15 hours ago
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business's STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders. Future Labs is part of Apimeds' ai² innovation platform, connectin.
Neutral
Business Wire
1 month ago
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Dr. Kramer brings more than 30 year.
Neutral
GlobeNewsWire
3 months ago
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol “APUS.”
Positive
Seeking Alpha
3 months ago
U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading
A few new issuers went public this past week, joined by two SPACs. Three IPOs are scheduled to list in the week ahead, although some small deals may join the calendar at the last minute. Street research is expected for three companies in the week ahead, and one lock-up period will be expiring.
Neutral
GlobeNewsWire
3 months ago
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share.
Charts implemented using Lightweight Charts™